Me is closing its therapeutics division and will wind down ongoing clinical trials, the struggling genetic testing company ...

The FDA has removed a clinical hold on Novavax’s flu-Covid combination shot and standalone flu vaccine, less than a month ...

Rapt Therapeutics is officially shelving its mid-stage immunology candidate after a case of liver failure triggered clinical ...

Thermo Fisher is closing a factory in Lexington, MA, and merging operations with a newer facility in Plainville, MA, to ...

Assertio Holdings responded to activist investor Alexander Parker after Parker's firm accused Assertio of fraud. The Buxton Helmsley Group on Friday released an open letter to Assertio’s stockholders, ...

The centerpiece of AbbVie’s $8.7 billion Cerevel acquisition just imploded. Emraclidine, a schizophrenia program expected to ...

A Danish company is spending $145 million upfront for certain rights to the first-ever needle-free adrenaline nasal spray for severe allergic reactions, unlocking sales potential of more than $400 ...

The eye giant Alcon has launched an unlikely legal battle, suing a cell therapy startup that it invested in and claiming its shareholder rights are being violated as Aurion Biotech ...

Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attention as potential treatments for a variety of ...

The FDA this week posted an untitled letter sent Oct. 17 to China-based active pharmaceutical ingredient (API) manufacturer ...

Amgen and AstraZeneca said on Friday that their asthma drug Tezspire reduced nasal congestion and the size of nasal polyps in patients with a different but sometimes related inflammatory condition ...

Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most ...